Literature DB >> 17948870

Chromosome 4q31-34 panic disorder risk locus: association of neuropeptide Y Y5 receptor variants.

Katharina Domschke1, Christa Hohoff, Christian Jacob, Wolfgang Maier, Jürgen Fritze, Borwin Bandelow, Petra Krakowitzky, Florian Kästner, Matthias Rothermundt, Volker Arolt, Jürgen Deckert.   

Abstract

There is strong evidence for a genetic contribution to the pathogenesis of panic disorder, with a recent linkage study pointing toward a risk locus on chromosome 4q31-q34 [Kaabi et al., 2006]. Since the neuropeptide Y (NPY) system has been reported to be involved in the pathophysiology of anxiety and in particular panic disorder and the genes coding for NPY Y1, Y2, and Y5 receptors are located in the suggested risk region (4q31-q32), variants in the NPY, NPY Y1, Y2, and Y5 genes were investigated for association with panic disorder in a sample of 230 German patients with panic disorder and matched healthy controls. A synonymous (Gly-426-Gly) NPY Y5 coding variant (rs11946004) as well as haplotypes including rs11946004 and an intronic NPY Y5 variant (rs11724320) were significantly associated with panic disorder (P = 0.027), with the effect originating from the subgroup of female patients (P = 0.030), particularly with concurrent agoraphobia (P = 0.002-0.019). No association was observed for any variants located in the genes coding for NPY, NPY Y1, or Y2. The present results provide preliminary support for an influence of NPY Y5 receptor variants on the etiology of panic disorder in a potentially gender-specific manner further strengthening the evidence for a risk locus on chromosome 4q31-q34 in anxiety disorders. However, in order to allow for conclusive evaluation of the present finding and to exclude a false positive result, further studies in larger, independent, preferably family based samples are warranted. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17948870     DOI: 10.1002/ajmg.b.30629

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  13 in total

Review 1.  Candidate genes in panic disorder: meta-analyses of 23 common variants in major anxiogenic pathways.

Authors:  A S Howe; H N Buttenschøn; A Bani-Fatemi; E Maron; T Otowa; A Erhardt; E B Binder; N O Gregersen; O Mors; D P Woldbye; K Domschke; A Reif; J Shlik; S Kõks; Y Kawamura; A Miyashita; R Kuwano; K Tokunaga; H Tanii; J W Smoller; T Sasaki; D Koszycki; V De Luca
Journal:  Mol Psychiatry       Date:  2015-09-22       Impact factor: 15.992

2.  ADORA2A Gene variation, caffeine, and emotional processing: a multi-level interaction on startle reflex.

Authors:  Katharina Domschke; Agnieszka Gajewska; Bernward Winter; Martin J Herrmann; Bodo Warrings; Andreas Mühlberger; Katherina Wosnitza; Evelyn Glotzbach; Annette Conzelmann; Andrea Dlugos; Manfred Fobker; Christian Jacob; Volker Arolt; Andreas Reif; Paul Pauli; Peter Zwanzger; Jürgen Deckert
Journal:  Neuropsychopharmacology       Date:  2011-10-19       Impact factor: 7.853

3.  Mechanism of action in CBT (MAC): methods of a multi-center randomized controlled trial in 369 patients with panic disorder and agoraphobia.

Authors:  A T Gloster; H U Wittchen; F Einsle; M Höfler; T Lang; S Helbig-Lang; T Fydrich; L Fehm; A O Hamm; J Richter; G W Alpers; A L Gerlach; A Ströhle; T Kircher; J Deckert; P Zwanzger; V Arolt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-11       Impact factor: 5.270

Review 4.  The diagnosis of and treatment recommendations for anxiety disorders.

Authors:  Borwin Bandelow; Thomas Lichte; Sebastian Rudolf; Jörg Wiltink; Manfred E Beutel
Journal:  Dtsch Arztebl Int       Date:  2014-07-07       Impact factor: 5.594

Review 5.  Anxiety in mice and men: a comparison.

Authors:  Christa Hohoff
Journal:  J Neural Transm (Vienna)       Date:  2009-04-02       Impact factor: 3.575

6.  Meta-analysis of genome-wide association studies for panic disorder in the Japanese population.

Authors:  T Otowa; Y Kawamura; N Nishida; N Sugaya; A Koike; E Yoshida; K Inoue; S Yasuda; Y Nishimura; X Liu; Y Konishi; F Nishimura; T Shimada; H Kuwabara; M Tochigi; C Kakiuchi; T Umekage; T Miyagawa; A Miyashita; E Shimizu; J Akiyoshi; T Someya; T Kato; T Yoshikawa; R Kuwano; K Kasai; N Kato; H Kaiya; K Tokunaga; Y Okazaki; H Tanii; T Sasaki
Journal:  Transl Psychiatry       Date:  2012-11-13       Impact factor: 6.222

7.  Targeting the Neuropeptide Y System in Stress-related Psychiatric Disorders.

Authors:  Nicole M Enman; Esther L Sabban; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Neurobiol Stress       Date:  2015-01-01

Review 8.  Neuropeptide Y in Alcohol Addiction and Affective Disorders.

Authors:  Annika Thorsell; Aleksander A Mathé
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-31       Impact factor: 5.555

Review 9.  Neuropeptide Y: A stressful review.

Authors:  Florian Reichmann; Peter Holzer
Journal:  Neuropeptides       Date:  2015-09-30       Impact factor: 3.286

10.  A functional genetic variation of SLC6A2 repressor hsa-miR-579-3p upregulates sympathetic noradrenergic processes of fear and anxiety.

Authors:  L G Hommers; J Richter; Y Yang; A Raab; C Baumann; K Lang; M A Schiele; H Weber; A Wittmann; C Wolf; G W Alpers; V Arolt; K Domschke; L Fehm; T Fydrich; A Gerlach; A T Gloster; A O Hamm; S Helbig-Lang; T Kircher; T Lang; C A Pané-Farré; P Pauli; B Pfleiderer; A Reif; M Romanos; B Straube; A Ströhle; H-U Wittchen; S Frantz; G Ertl; M J Lohse; U Lueken; J Deckert
Journal:  Transl Psychiatry       Date:  2018-10-19       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.